Abstract
Epithelioid hemangioendothelioma is an ultra-rare cancer driven by YAP–CAMTA1 fusion. Based on the link of the fusion to the MEK pathway, SARC33 was performed. It is a phase 2 trial examining trametinib that missed its primary objective by RECIST but demonstrated patient-reported outcome benefits in improved pain.
Original language | English |
---|---|
Pages (from-to) | 4552-4553 |
Number of pages | 2 |
Journal | Clinical Cancer Research |
Volume | 30 |
Issue number | 20 |
DOIs | |
State | Published - Oct 15 2024 |